Joint (JYNT) AI Stock Analysis

• Market Cap: $166.94M
• Dividend Yield: N/A
• Average Volume (3M): 64.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: -40.65%
• EPS Growth: 85.56%
• Country: US
• Employees: 443
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Care Facilities
• EPS (TTM): -0.05
• Shares Outstanding: 15,343,377
• 10 Day Avg. Volume: 103,045
• 30 Day Avg. Volume: 64,936
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 1.69
• Enterprise Value/Gross Profit: 1.96
• Enterprise Value/Ebitda: -914.68
• 1Y Price Target: $14.00
• Price Target Upside: 30.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 52 Neutral
• Price Target: $10.50 ▼(-1.87% Downside)

The overall stock score is primarily influenced by financial performance challenges, including consistent net losses and cash flow sustainability issues. While technical indicators suggest bearish momentum, recent corporate events and earnings call insights provide some optimism with strategic shifts and improved EBITDA.

Positive Factors

Digital Strategy

The Joint is advancing its digital strategy, with increased online scheduling capabilities and the launch of its first mobile app expected, which could improve the patient experience and drive repeat visits.

Financial Stability

JYNT had $29.8M in unrestricted cash and no debt, and is expected to generate positive cash flows from continuing operations.

Operational Efficiency

The recent deal to refranchise 31 clinics and reacquire regional developer territory rights for the Northwest region for $8.3M is viewed as a positive step toward operational efficiency and strategic clarity.

Negative Factors

Execution Risks

Execution risks remain, as the company has yet to finalize the sale of a significant number of corporate-owned clinics.

Sales Outlook

JYNT's reduced sales outlook and weakening revenue growth reflect mounting headwinds in patient acquisition and a deliberate slowdown in clinic expansion.

Uncertainty

The potential sale, relocation, or closure of company-owned clinics creates uncertainty.

Joint Business Overview & Revenue Model

Company Description

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

How the Company Makes Money

Joint generates revenue primarily through the sale of its dietary supplements, which are marketed both directly to consumers via e-commerce platforms and through partnerships with health and wellness retailers. Key revenue streams include subscription services for regular customers, one-time purchases, and bulk orders from healthcare providers. Additionally, Joint may benefit from strategic partnerships with fitness centers and physical therapy clinics, enhancing its market reach and brand visibility. The company's focus on continuous product development and customer engagement through educational content also contributes to customer loyalty and repeat sales.

Joint Financial Statement Overview

Summary

Joint faces challenges with profitability and cash flow sustainability despite maintaining reasonable margins and low leverage. The decline in revenue and equity over recent periods highlights potential financial instability, and consistent net losses are a significant concern for future growth.

Income Statement

The company has seen fluctuating revenue with a notable decline from 2023 to TTM (Trailing-Twelve-Months). Gross profit margin remains strong at approximately 63.5% for TTM. However, the consistent negative EBIT and net loss indicate ongoing operational challenges and profitability issues, as evidenced by negative net profit margins.

Balance Sheet

The balance sheet shows reasonable stability with a debt-to-equity ratio of about 0.11 in TTM, indicating low leverage. However, the decline in equity over the years and the low return on equity due to negative net income suggest potential financial stress. The equity ratio stands at 25.8%, showing moderate reliance on equity financing.

Cash Flow

Cash flow analysis shows positive operating cash flow, but decreasing over the periods. Free cash flow is positive but has been inconsistent, reflecting challenges in maintaining cash generation. The operating cash flow to net income ratio is negative due to consistent net losses, highlighting potential cash flow sustainability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	87.98M	51.90M	117.70M	101.25M	80.01M	58.68M
Gross Profit	75.83M	40.38M	107.15M	92.08M	72.68M	52.18M
EBITDA	-162.81K	2.98M	9.14M	7.89M	10.07M	8.18M
Net Income	-8.68M	-8.53M	-9.75M	626.71K	7.57M	13.17M
Balance Sheet
Total Assets	77.19M	80.42M	87.15M	91.94M	84.04M	65.73M
Cash, Cash Equivalents and Short-Term Investments	21.92M	25.05M	18.15M	9.75M	19.53M	20.55M
Total Debt	2.25M	448.29K	2.86M	26.06M	23.62M	18.48M
Total Liabilities	57.26M	62.48M	62.38M	60.90M	56.75M	44.75M
Stockholders Equity	19.91M	17.92M	24.75M	32.37M	29.54M	20.75M
Cash Flow
Free Cash Flow	1.78M	8.23M	9.68M	2.31M	6.85M	6.99M
Operating Cash Flow	2.90M	9.42M	14.68M	11.08M	15.23M	11.18M
Investing Cash Flow	-578.01K	-631.55K	-6.19M	-20.78M	-14.14M	-4.60M
Financing Cash Flow	904.66K	-2.00M	174.12K	328.61K	-2.00M	5.60M

Joint Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JYNT, the sentiment is Negative. The current price of 10.7 is below the 20-day moving average (MA) of 10.80, below the 50-day MA of 11.23, and below the 200-day MA of 11.07, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 45.77 is Neutral, neither overbought nor oversold. The STOCH value of 67.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JYNT.

Joint Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTH	72 Outperform	$1.51B	58.68	3.50%	―	51.97%	-64.10%
USPH	71 Outperform	$1.28B	36.75	7.02%	2.12%	16.24%	116.58%
NHC	69 Neutral	$1.73B	16.61	10.65%	2.21%	25.19%	13.44%
TOI	55 Neutral	$326.33M	―	-535.24%	―	17.53%	14.49%
JYNT	52 Neutral	$166.94M	―	-16.16%	―	-40.65%	85.56%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
MODV	41 Neutral	$8.29M	―	-951.52%	―	-0.70%	-2.38%

Joint Corporate Events

Joint Announces CFO Resignation and Separation Agreement

Joint company announced the resignation of its Chief Financial Officer, Mr. Singleton, effective June 9, 2025. A separation agreement was established on August 22, 2025, which includes a general release of all claims. If Mr. Singleton does not revoke the agreement, he will receive separation benefits including cash payments and COBRA coverage. The agreement outlines the treatment of his equity awards, which will not receive accelerated vesting.

Joint Corp. Reports Q2 2025 Financial Results

The Joint Corp. reported its second quarter 2025 financial results, highlighting a 5% revenue growth to $13.3 million and a significant improvement in net income from a loss of $3.6 million in Q2 2024 to a profit of $93,000. The company refranchised 37 clinics, acquired rights to the Northwest regional developer territory, and increased its franchised clinics to 92% of its portfolio. The company is focusing on enhancing its brand campaign and improving its marketing infrastructure to drive long-term sales, while also planning nominal price increases to balance affordability and patient value.

Joint Corp. Sells Clinics, Acquires Developer Rights

On June 30, 2025, The Joint Corp. completed the sale of 31 company-owned clinics in Arizona and New Mexico to Joint Ventures, LLC for $8.3 million and acquired regional developer rights in the Northwest Region. This transaction is part of The Joint Corp.’s strategy to strengthen and simplify its business by transferring clinics to proven franchise operators, while acquiring regional developer rights to reduce commission obligations and increase operating margins, thus enhancing value for stakeholders.

Joint Corp. Sells Clinics in Strategic Move

On June 23, 2025, The Joint Corp. entered into an Asset Purchase Agreement with Joint Ventures, LLC to sell 31 company-owned clinics in Arizona and New Mexico for $11.07 million. This transaction, expected to close by June 30, 2025, also involves acquiring regional developer rights in the Northwest Region, which includes 46 existing franchised clinics and 30 future development sites. Additionally, The Joint Corp. refranchised five clinics in Kansas and Missouri to Chiro 93, LLC. These strategic moves aim to enhance The Joint’s profitability and solidify its position as the largest pure play chiropractic care franchise system.

Joint Corp. Appoints New CFO Scott J. Bowman

On June 10, 2025, The Joint Corp. announced the appointment of Scott J. Bowman as its new Chief Financial Officer, succeeding Jake Singleton. Bowman, who brings over 30 years of experience in finance, has previously served as CFO at several public companies, including Leslie’s, Inc. and Dave & Buster’s. His expertise in capital markets and strategic planning is expected to support The Joint Corp.’s strategy to reignite growth and improve profitability. The company aims to transform into a pure play franchisor and enhance its position as a leading health and wellness services provider in the U.S.

Joint Corp. Appoints New Director and Chair

On June 3, 2025, The Joint Corp.’s Board of Directors expanded its size and appointed Sandi Karrmann as a new director, who will also serve as Chair of the Compensation Committee. Karrmann, with extensive experience in human resources and healthcare, is expected to contribute to the company’s strategic goals of enhancing talent and culture to boost growth and profitability. Additionally, the Board approved a stock repurchase plan to buy back up to $5 million of common stock by June 2027, aiming to optimize capital structure and enhance shareholder value.